Regent Pacific Group Limited Stock Hong Kong S.E.
Stocks
575
KYG3042R1231
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4700 HKD | -.--% |
|
-17.54% | -24.19% |
| 06-17 | Regent Pacific's Senstend Approved in China | MT |
| 06-16 | Regent Pacific Group Limited Receives NMPA Approval For Senstend And Announces Commercialisation in China | CI |
| Market Cap | 33.48M 263M 29.05M 27.2M 24.88M 46.98M 3.19B 47.59M 318M 125M 1.59B 126M 123M 5.3B | P/E 2024 |
-2.39x | P/E 2025 | -7.63x |
|---|---|---|---|---|---|
| Enterprise Value | 37.26M 292M 32.34M 30.28M 27.7M 52.29M 3.55B 52.97M 354M 139M 1.77B 140M 137M 5.9B | EV / Sales 2024 |
19.4x | EV / Sales 2025 | 121x |
| Free-Float |
31.54% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Jamie Gibson
CEO | Chief Executive Officer | 60 | 2002-04-30 |
Yui Fui Wong
DFI | Director of Finance/CFO | 51 | 2010-12-31 |
Michael Wyllie
CTO | Chief Tech/Sci/R&D Officer | 75 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jamie Gibson
BRD | Director/Board Member | 60 | 2001-12-31 |
| Director/Board Member | 62 | 2000-05-31 | |
Jim Mellon
CHM | Chairman | 70 | 1993-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -17.54% | - | - | 33.48M | |
| +1.89% | +3.20% | +59.70% | +165.18% | 1,062B | |
| -0.24% | +0.45% | +50.64% | +52.02% | 619B | |
| -0.95% | -5.26% | +24.23% | +65.08% | 431B | |
| +1.81% | +5.12% | +49.22% | +40.34% | 358B | |
| +0.98% | -0.03% | +36.01% | +40.86% | 293B | |
| +1.27% | -5.08% | +9.50% | +10.14% | 247B | |
| -0.73% | +4.44% | +42.22% | +66.41% | 219B | |
| +3.63% | -0.57% | -1.33% | -44.15% | 200B | |
| -0.68% | -0.32% | +18.66% | +66.32% | 162B | |
| Average | +0.84% | -1.90% | +32.09% | +51.36% | 399.14B | |
| Weighted average by Cap. | +0.66% | -0.83% | +41.13% | +78.26% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 719K 5.64M 624K 584K 534K 1.01M 68.49M 1.02M 6.84M 2.68M 34.22M 2.7M 2.64M 114M | 363K 2.85M 315K 295K 270K 509K 34.58M 516K 3.45M 1.35M 17.28M 1.36M 1.33M 57.5M |
| Net income | -4.48M -35.16M -3.89M -3.64M -3.33M -6.29M -427M -6.37M -42.61M -16.72M -213M -16.83M -16.46M -710M | -4.71M -36.95M -4.09M -3.83M -3.5M -6.61M -449M -6.7M -44.78M -17.57M -224M -17.68M -17.3M -746M |
| Net Debt | 3.22M 25.24M 2.79M 2.61M 2.39M 4.51M 306M 4.57M 30.58M 12M 153M 12.08M 11.82M 510M | 3.78M 29.68M 3.28M 3.07M 2.81M 5.31M 360M 5.38M 35.96M 14.11M 180M 14.2M 13.89M 599M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 575 Stock
- 575 Stock
Select your edition
All financial news and data tailored to specific country editions
